Akari Therapeutics

If PH1‑based ADCs show meaningful efficacy and safety differentiation, oncology pricing headroom could be significant relative to standard chemotherapy, but that is hypothetical today.

Competitors with approved Trop2 ADCs (e.g., Dato‑DxD) already set reference pricing and payer expectations, limiting incremental pricing latitude for a later entrant unless it delivers superior outcomes or clear safety advantages. With no revenue and no clinical data in humans yet, realized pricing power is minimal.